L-Ornithine-L-Aspartate
OTHER NAME(S): 2,5-Diaminopentanoic Acid 2-Aminobutanedioic Acid, L-Ornithin-L-Aspartat, L-Ornithine-L-Aspartate Salt, LOLA, Ornithine Aspartate, Ornithylaspartate, L-Ornithine-L-Aspartate, L-Ornthine-L-Aspartate, L-Orinthine-L-Aspartate
Overview
L-ornithine-L-aspartate is a chemical that is broken down by the body to increase levels of two amino acids: ornithine and aspartic acid.
Ornithine and aspartic acid help to reduce levels of a toxic chemical called ammonia in the blood.
L-ornithine-L-aspartate increases the levels of ornithine and aspartic acid in the body. These amino acids help to reduce levels of a toxic chemical called ammonia in the blood.
People use L-ornithine-L-aspartate for reduced brain function due to advanced liver disease (hepatic encephalopathy). It is also used for athletic performance, cirrhosis, and other purposes, but there is no good scientific evidence to support these uses.
Don't confuse L-ornithine-L-aspartate with ornithine or aspartic acid. These are not the same.
L-ornithine-L-aspartate increases the levels of ornithine and aspartic acid in the body. These amino acids help to reduce levels of a toxic chemical called ammonia in the blood.
Uses
Possibly Effective for
- Reduced brain function in people with advanced liver disease (hepatic encephalopathy). Taking L-ornithine-L-aspartate by mouth or by IV might reduce symptoms of this condition in people with a long-term liver disease called cirrhosis. But it does not seem to help in those with short-term liver failure. IV products can only be given by a healthcare provider.
There is interest in using L-ornithine-L-aspartate for a number of other purposes, but there isn't enough reliable information to say whether it might be helpful.
Side Effects
When taken by mouth: L-ornithine-L-aspartate is possibly safe when used in doses of up to 18 grams daily for up to 6 months. It's generally well-tolerated.
Precautions
When taken by mouth: L-ornithine-L-aspartate is possibly safe when used in doses of up to 18 grams daily for up to 6 months. It's generally well-tolerated.
Pregnancy and breast-feeding: There isn't enough reliable information to know if L-ornithine-L-aspartate is safe to use when pregnant or breast-feeding. Stay on the safe side and avoid use.
Interactions
We currently have no information for L-Ornithine-L-Aspartate overview.
Dosing
L-ornithine-L-aspartate has most often been used by adults in doses of 6-18 grams by mouth daily for up to 6 months. Speak with a healthcare provider to find out what dose might be best for a specific condition.
References
- Rees C, Oppong K, Mardini H, et al. Effect of L-Ornithine-L-Aspartate on patients with and without TIPS undergoing glutamine challenge: a double blind, placebo controlled trial. Gut 2000;47:571-4..
- Kowalski, P. and Bieniecki, M. Pharmacokinetics and bioavailability study of L-ornithine-L-aspartate in healthy volunteers--a comparative study of two oral formulations. J.Pharm.Biomed.Anal. 6-7-2006;41(3):1061-1064.
- Poo, J. L., Gongora, J., Sanchez-Avila, F., Aguilar-Castillo, S., Garcia-Ramos, G., Fernandez-Zertuche, M., Rodriguez-Fragoso, L., and Uribe, M. Efficacy of oral L-ornithine-L-aspartate in cirrhotic patients with hyperammonemic hepatic encephalopathy. Results of a randomized, lactulose-controlled study. Ann.Hepatol. 2006;5(4):281-288.
- Ahmad, I., Khan, A. A., Alam, A., Dilshad, A., Butt, A. K., Shafqat, F., Malik, K., and Sarwar, S. L-ornithine-L-aspartate infusion efficacy in hepatic encephalopathy. J.Coll.Physicians Surg.Pak. 2008;18(11):684-687.
- Acharya, S. K., Bhatia, V., Sreenivas, V., Khanal, S., and Panda, S. K. Efficacy of L-ornithine L-aspartate in acute liver failure: a double-blind, randomized, placebo-controlled study. Gastroenterology 2009;136(7):2159-2168.
- Ong, J. P., Oehler, G., Kruger-Jansen, C., Lambert-Baumann, J., and Younossi, Z. M. Oral L-ornithine-L-aspartate improves health-related quality of life in cirrhotic patients with hepatic encephalopathy: an open-label, prospective, multicentre observational study. Clin.Drug Investig. 2011;31(4):213-220.
- Ndraha, S., Hasan, I., and Simadibrata, M. The effect of L-ornithine L-aspartate and branch chain amino acids on encephalopathy and nutritional status in liver cirrhosis with malnutrition. Acta Med.Indones. 2011;43(1):18-22.
- Mittal, V. V., Sharma, B. C., Sharma, P., and Sarin, S. K. A randomized controlled trial comparing lactulose, probiotics, and L-ornithine L-aspartate in treatment of minimal hepatic encephalopathy. Eur.J.Gastroenterol.Hepatol. 2011;23(8):725-732.
- Kircheis, G., Nilius, R., Held, C., Berndt, H., Buchner, M., Gortelmeyer, R., Hendricks, R., Kruger, B., Kuklinski, B., Meister, H., Otto, H. J., Rink, C., Rosch, W., and Stauch, S. Therapeutic efficacy of L-ornithine-L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: results of a placebo-controlled, double-blind study. Hepatology 1997;25(6):1351-1360.
- Stauch, S., Kircheis, G., Adler, G., Beckh, K., Ditschuneit, H., Gortelmeyer, R., Hendricks, R., Heuser, A., Karoff, C., Malfertheiner, P., Mayer, D., Rosch, W., and Steffens, J. Oral L-ornithine-L-aspartate therapy of chronic hepatic encephalopathy: results of a placebo-controlled double-blind study. J.Hepatol. 1998;28(5):856-864.
- Feher J, Lang I Gogl A Varga L Varga L Tompos G Pronai L. Effect of ornithine-aspartate infusion on elevated serum ammonia concentration in cirrhotic patients - Results of a randomized, placebo-controlled double-blind multicentre trial. Medical Science Monitor. 1997;3(5):669-673.
- Schmid M, Peck-Radosavljevic M König F Mittermaier C Gangl A Ferenci P. A double-blind, randomized, placebo-controlled trial of intravenous L-ornithine-L-aspartate on postural control in patients with cirrhosis. Liver Int. 2010;30(4):574-582.
- Alvares-da-Silva MR, de Araujo A, Vicenzi JR, et al. Oral L-ornithine-L-aspartate in minimal hepatic encephalopathy: a randomized, double-blind, placebo-controlled trial. Hepatol Res 2014;44:956-63.
- Waghray A, Waghray N, Mullen K. Management of covert hepatic encephalopathy. J Clin Exp Hepatol 2015;5:S75-81.
- Shalimar, Acharya SK. Management in acute liver failure. J Clin Exp Hepatol 2015;5:S104-15.
- Zhu GQ, Shi KQ, Huang S, et al. Systematic review with network meta-analysis: the comparative effectiveness and safety of interventions in patients with overt hepatic encephalopathy. Aliment Pharmacol Ther 2015;41:624-35.
- Bai M, He C, Yin Z, et al. Randomised clinical trial: L-ornithine-L-aspartate reduces significantly the increase of venous ammonia concentration after TIPSS. Aliment Pharmacol Ther 2014;40:63-71.
- Pérez Hernández JL, Higuera de la Tijera F, Serralde-Zúñiga AE, Abdo Francis JM. Critical analysis of studies evaluating the efficacy of infusion of L-ornithine L-aspartate in clinical hepatic encephalopathy in patients with liver failure. Ann Hepatol 2011;10 Suppl 2:S66-9.
- Abid S, Jafri W, Mumtaz K, et al. Efficacy of L-ornithine-L-aspartate as an adjuvant therapy in cirrhotic patients with hepatic encephalopathy. J Coll Physicians Surg Pak 2011;21:666-71.
- Sharma K, Pant S, Misra S, et al. Effect of rifaximin, probiotics, and l-ornithine l-aspartate on minimal hepatic encephalopathy: a randomized controlled trial. Saudi J Gastroenterol 2014;20:225-32.
- Mikulski T, Dabrowski J, Hilgier W, et al. Effects of supplementation with branched chain amino acids and ornithine aspartate on plasma ammonia and central fatigue during exercise in healthy men. Folia Neuropathol 2015;53:377-86.
- Bai M, Yang Z, Qi X, et al. L-ornithine-L-aspartate for hepatic encephalopathy in patients with cirrhosis: a meta-analysis of randomized controlled trials. J Gastroenterol Hepatol 2013;28:783-92.
- Goh ET, Stokes CS, Sidhu SS, Vilstrup H, Gluud LL, Morgan MY. L-onrhithine L-aspartate for prevention and treatment of hepatic encephalopathy in people with cirrhosis. Cochrane Database Syst Rev. 2018 May 15;5:CD012410.
- Varakanahalli S, Sharma BC, Srivastava S, Sachdeva S, Dahale AS. Secondary prophylaxis of hepatic encephalopathy in cirrhosis of liver: a double-blind randomized controlled trial of L-ornithine L-aspartate versus placebo. Eur J Gastroenterol Hepatol. 2018 Apr 30.
- Alehagen U, Alexander J, Aaseth J. Supplementation with selenium and coenzyme Q10 reduces cardiovascular mortality in elderly with low selenium status. A secondary analysis of a randomized clinical trial. PLoS One. 2016 Jul 1;11(7):e0157541.
- Jain A, Sharma BC, Mahajan B, et al. L-ornithine L-aspartate in acute treatment of severe hepatic encephalopathy: A double-blind randomized controlled trial. Hepatology. 2022;75(5):1194-203.